| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541171 | ABBVIE | Orally administrable pharmaceutical composition |
Jul, 2013
(10 years ago) | |
| US5541170 | ABBVIE | Orally administrable pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
| US6649180 | ABBVIE | Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups |
Apr, 2020
(4 years ago) | |
Delzicol is owned by Abbvie.
Delzicol contains Mesalamine.
Delzicol has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Delzicol are:
- US5541171
- US5541170
- US6649180
Delzicol was authorised for market use on 01 February, 2013.
Delzicol is available in capsule, delayed release;oral dosage forms.
Delzicol can be used as treatment of ulcerative colitis.
The generics of Delzicol are possible to be released after 13 April, 2020.
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 01 February, 2013
Treatment: Treatment of ulcerative colitis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
How can I launch a generic of DELZICOL before it's drug patent expiration?
More Information on Dosage
DELZICOL family patents
